Clinical trials: Placebo Group
Migraine
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 [monthly TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3 months] compared with placebo for preventive…
- Trial name
- NCT03303079
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 571 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Multiple Sclerosis Relapse
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
The primary objective was to demonstrate the effect of teriflunomide, in comparison to placebo, on frequency of Multiple Sclerosis (MS) relapses in patients with relapsing forms of MS who are treated with Interferon-beta…
- Trial name
- TERACLES (NCT01252355)
- Testing
- Teriflunomide, Interferon-beta (IFN-beta)
- Where
- 185 sites in United States, Argentina and 26 more
- Volunteers
- 534 people
- Sponsor
- Sanofi
Osteoporosis, Postmenopausal
Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)
Efficacy: To investigate changes of structural bone properties in vivo using 3DpQCT ("Xtreme" CT, Scanco) in monthly oral ibandronate therapy for women with postmenopausal osteoporosis.
- Trial name
- NCT00271713
- Testing
- ibandronate, calcium and vitamin D
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Charite University, Berlin, Germany
Healthy
A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers
This study is designed to evaluate the safety, tolerability and pharmacokinetics (PK) of two doses of AZD1446 or placebo in subjects when given for 4 weeks.
- Trial name
- NCT00997308
- Testing
- AZD1446
- Where
- Sweden
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure
Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure
A Study to Evaluate Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of HNO Donor in Hospitalized Patients with Heart Failure and Impaired Systolic Function
- Trial name
- STANDUP AHF (NCT03016325)
- Testing
- HNO Donor
- Where
- 116 sites in United States, Argentina and 11 more
- Volunteers
- 329 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes
GALLANT 7 Tesaglitazar Add-on to Sulphonylurea
This is a 24-week randomized double-blind, parallel-group, multi-center, placebo-controlled study of tesaglitazar (0.5 mg and 1 mg) given as add-on therapy to sulphonylurea in patients with type 2 diabetes, not adequately…
- Trial name
- NCT00251940
- Testing
- Tesaglitazar 0.5 or 1 mg, Glibenclamide 2.5, 5, 10 or 15 mg
- Where
- 84 sites in Australia, France and 8 more
- Volunteers
- 555 people
- Sponsor
- AstraZeneca
Ankle Sprain
Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain
The purpose of this study is to evaluate the efficacy of diclofenac potassium 25 mg tablet compared with placebo taken three times a day in subjects with acute ankle sprains under 'in-use' conditions, in particular with regard to…
- Trial name
- NCT01666197
- Testing
- diclofenac potassium 25 mg tablet
- Where
- 4 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Novartis
Healthy
Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects
This is a double-blind, randomised, placebo-controlled 3 period study to evaluate the interaction between a drug and CNV1014802 in healthy male and female subjects. It is planned to enrol 36 subjects.
- Trial name
- NCT02551497
- Testing
- CNV1014802
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Biogen
Pneumonia, Viral
Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS
The goal of this study is to evaluate the effects of Ibudilast (MN-166) versus placebo in hospitalized patients infected with COVID-19 at risk for developing acute respiratory distress syndrome (ARDS) receiving standard of care…
- Trial name
- NCT04429555
- Testing
- Ibudilast
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- MediciNova
Hypercholesterolemia
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
The purpose of this study is to test the effectiveness of the study drug, AEGR-733 alone and in combination with the medication, atorvastatin (Lipitor), on cholesterol in volunteers with moderately high cholesterol.
- Trial name
- NCT00474240
- Testing
- Atorvastatin 20 mg, AEGR-733 5 mg, AEGR-733 10 mg
- Where
- 17 sites in United States
- Volunteers
- 157 people
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Herpes Genitalis
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Genital herpes (GH) is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are two types of HSV, type 1 (HSV-1) and type 2 (HSV-2); both can cause GH, although the latter is much more…
- Trial name
- NCT00158860
- Testing
- Valaciclovir
- Where
- 72 sites in United States, Argentina and 3 more
- Volunteers
- 384 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder
The study will assess efficacy, safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine in patients with Major Depressive Disorder.
- Trial name
- NCT01110889
- Testing
- Agomelatine (AGO178C)
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 582 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis
This study is open to adults with plaque psoriasis. The main purpose of this study is to find out whether people with plaque psoriasis can tolerate a medicine called BI 765250.
- Trial name
- NCT05728489
- Testing
- BI 765250
- Where
- 5 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 64 people
- Sponsor
- Boehringer Ingelheim
Painful Diabetic Neuropathy
Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain
The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate (ESL) as therapy in subjects with Diabetic Neuropathic Pain (DNP) over a 15 week treatment phase.
- Trial name
- NCT01129960
- Testing
- Eslicarbazepine acetate (BIA 2-093)
- Where
- Portugal
- Volunteers
- 332 people
- Sponsor
- Bial - Portela C S.A.
Insomnia
A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
This study will establish the safety and tolerability of suvorexant (MK-4305) when administered for up to 14 months. Participants will be randomized to receive suvorexant or placebo for a 12-month double-blind (DB) Treatment…
- Trial name
- NCT01021813
- Testing
- Suvorexant
- Volunteers
- 781 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a…
- Trial name
- NCT07697560
- Testing
- AH-008 for Injection, 150 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Diabetes Mellitus, Type 2
Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus
PF-04603629 is being investigated for the treatment of Type 2 diabetes mellitus (T2DM). Specifically, PF-04603629 is a protein that is a combination of exendin-4 (a glucagon-like peptide-1 (GLP-1) mimetic currently marketed as…
- Trial name
- NCT00637338
- Testing
- PF-04603629
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, Hypertension
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
This trial will evaluate safety and efficacy of BI 10773 in hypertensive patients with type 2 diabetes. Since hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular complications, assessment of…
- Trial name
- NCT01370005
- Testing
- BI 10773
- Where
- 120 sites in United States, Canada and 10 more
- Volunteers
- 825 people
- Sponsor
- Boehringer Ingelheim
Traumatic Brain Injury
Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression
The purpose of this study is to determine if carbamazepine reduces irritability and aggression among individuals with traumatic brain injury
- Trial name
- NCT00621751
- Testing
- Carbamazepine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Wake Forest University Health Sciences
Refractory Partial Seizures
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
The purpose of this study is to evaluate the safety, efficacy and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.
- Trial name
- NCT00699972
- Testing
- E2007 (perampanel)
- Where
- 97 sites in United States, Argentina and 4 more
- Volunteers
- 390 people
- Sponsor
- Eisai Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.